

Denintuzumab

| | |
|-----------|---|
| Cat. No.: | HY-P99285 |
| CAS No.: | 1630074-14-4 |
| Target: | ADC Antibody; CD19 |
| Pathway: | Antibody-drug Conjugate/ADC Related; Immunology/Inflammation |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia ^[1] . |
| IC ₅₀ & Target | CD19 ^[1] . |

REFERENCES

[1]. Farhadfar N, et al. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leuk Res. 2016 Oct;49:13-21.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA